When King Charles III and Catherine, Princess of Wales, shared their cancer diagnoses with the public in early 2024, the news rippled through the United Kingdom and far beyond. There was genuine sympathy, concern, and a renewed public conversation about cancer. But something else happened too. As the headlines multiplied, so did misinformation about cancer, treatment, prognosis, and so-called alternatives to conventional care. A new study published in ecancermedicalscience decided to take a closer look. Researchers from The Royal Marsden NHS Foundation Trust, King’s College London, the Royal College of Surgeons of England, the London School of Hygiene & Tropical Medicine, and Guy’s and St Thomas’ NHS Foundation Trust analyzed UK newspaper coverage after the royal announcements. What they found was sobering: roughly one in four stories contained false or factually inaccurate claims about cancer or cancer care. That statistic matters well beyond the Royal Family. When millions of people turn to the media for guidance during confusing and frightening moments, accuracy is not just a nice ideal. It can shape how people understand their health, the choices they make, and the trust they place in medical professionals.
The study focused on a specific period: the 40 days following the announcement of King Charles’s diagnosis on February 5, 2024, and that of Princess Catherine on March 22, 2024. The researchers searched 19 major UK newspapers and news websites and identified 72 stories that made claims related to cancer or cancer care. Two oncologists then assessed those claims, scoring them on a scale from entirely correct to clearly incorrect. The results were striking. Nineteen of the 72 stories, or 26 percent, were considered factually incorrect. Six of those stories were judged to be entirely incorrect in the cancer information they presented, while another thirteen contained at least some factual inaccuracies. The misinformation was not spread evenly across all topics. Among the inaccurate stories, 47 percent involved standard cancer treatments, 21 percent involved cancer epidemiology, and 16 percent involved complementary or alternative medicine. The problem was also unevenly distributed across the press. Sixteen of the nineteen inaccurate stories appeared in tabloid newspapers, and in ten of those stories, the journalist did not have a background in health journalism. In two cases, the journalist was not named at all. Some cancer claims were attributed to people with no medical background or with qualifications that were never clearly stated. The study’s authors point out that this is not just a statistical curiosity. When readers cannot tell whether a source is credible, they are left to sort out complex medical claims on their own.
Some of the misleading claims identified in the study show how easily the complexities of oncology can collapse into oversimplified, misleading soundbites. One recurring problem was the way chemotherapy was described. Chemotherapy can be curative in certain cancers and clinical situations, but its purpose varies widely depending on the type of cancer, the stage, the biology of the disease, and the overall treatment strategy. Some regimens are given with palliative intent, meaning they aim to control symptoms, prolong survival, or improve quality of life rather than cure the disease. Presenting chemotherapy broadly as “curative” creates unrealistic expectations. On the other side, some stories suggested that chemotherapy is only used for potentially curable cancers. That is also false. Chemotherapy and other systemic treatments are frequently used in advanced and metastatic cancers where a cure is not possible, but where treatment can slow the disease, reduce pain, or extend life. The study also flagged a claim that non-small cell lung cancer is usually treated with surgery. In reality, treatment depends heavily on the stage and tumor characteristics; many patients need systemic therapy, radiotherapy, or a combination of approaches. There is no single treatment that fits everyone. Another misleading theme involved hair loss. Popular culture has strongly tied cancer treatment to losing your hair and eyebrows, but the reality is more varied. The likelihood and degree of hair loss depend on the exact drugs, doses, and regimens. Many cancer treatments do not cause complete hair loss, and treating it as an inevitable part of every cancer journey can cause unnecessary fear and reinforce an outdated image of modern oncology. Perhaps the most concerning examples involved alternative medicine. Some reporting suggested that homeopathy could treat cancer. There is no credible evidence that homeopathy can treat or cure cancer. Complementary approaches may help with symptom management or wellbeing when used alongside standard care, but they should never be presented as substitutes for evidence-based treatment. The researchers also found an article that suggested a solar eclipse could be a hopeful sign for Princess Catherine’s recovery—a claim with no clinical relevance whatsoever.
Why does this matter so much? High-profile cancer diagnoses attract enormous public attention, and that attention can be beneficial. When public figures go public with their illness, it can encourage people to learn about cancer symptoms, schedule screenings, or have honest conversations with their doctors. It can help reduce stigma and make cancer feel less isolating. But there is a darker side. When limited clinical information is available, journalists may try to fill the gaps by speculating about possible treatments, prognosis, or causes without knowing the exact diagnosis, stage, molecular features, or treatment plan. In oncology, those details are everything. Two people with the same broad type of cancer may receive very different treatments and have very different outcomes depending on disease stage, tumor biology, biomarkers, and overall health. The study authors emphasize that media coverage can influence beliefs, health behavior, treatment expectations, and even how patients make decisions. That is a serious responsibility. The findings also reflect a wider challenge in health communication. In a crowded media environment, dramatic headlines and simple conclusions often overpower careful explanations of uncertainty and medical nuance. Previous research cited in the study found that media coverage tends to overstate the potential benefits of cancer drugs while giving less attention to treatment failure and side effects. That matters because many patients already begin their care with unrealistic expectations about how effective treatment will be. The study also highlights the importance of source transparency. When a story quotes an identifiable oncologist, a recognized medical organization, or a respected cancer institution, readers have a way of evaluating credibility. Vague descriptions like “leading doctors” or “medical experts” without names make that much harder. Transparent sourcing is not just a stylistic preference; it is a core part of responsible health communication.
If newspapers are struggling, social media may be an even greater challenge. The researchers argue that further investigation into cancer misinformation on digital platforms is urgently needed. Inaccurate or sensational health information can spread quickly and widely online, often faster than factual content. The authors cite research showing that social media posts containing health misinformation can get more engagement than posts that are accurate. Cancer is particularly vulnerable to this dynamic. Patients and families often search for information during moments of fear and uncertainty, when they may be especially receptive to miracle cures, hidden treatments, alternative therapies, or dramatic new breakthroughs. That is why the study’s recommendations are so important. Good cancer journalism does not require every reporter to become an oncologist. It does require strong sourcing, context, and careful language. Journalists and editors should name and credential every expert or organization they quote. They should rely on established medical organizations and peer-reviewed research. They should clearly distinguish between treatment intended to cure and treatment intended to control or palliate. They should avoid discussing prognosis without enough clinical information. They should explain that treatment decisions vary according to cancer type, stage, molecular characteristics, and individual patient factors. They should distinguish supportive or complementary care from disease-modifying treatment. They should identify unsupported alternative treatment claims as lacking evidence. They should explain the limitations of diagnostic tests rather than presenting them as universal solutions. And when errors are identified, they should correct them transparently. The study authors also call for closer collaboration between journalists and healthcare professionals, so that complex oncology information can be communicated accurately without becoming inaccessible to the public. Stricter verification standards, better education for journalists and editors, and stronger relationships between the press and the healthcare community are not optional extras. They are essential safeguards.
Of course, the study has important limitations. It examined only 72 stories published during a 40-day window following two highly unusual public cancer announcements. The relatively small sample meant that researchers could not perform meaningful statistical analysis. The findings should not be interpreted as proof that one quarter of all UK cancer journalism is inaccurate. Rather, the authors describe the analysis as offering a reasonable indication of national reporting trends at a particularly intense moment, while acknowledging that more research is needed. It is also worth remembering the distinction between misinformation and disinformation. Misinformation is false or misleading information that may be shared unintentionally. A journalist might oversimplify a complex treatment, repeat an outdated claim, or rely on an unreliable source without meaning to deceive. Disinformation, on the other hand, is false information deliberately created or shared to advance a political, ideological, commercial, or personal agenda. The key difference is intent. In cancer communication, both are harmful. An inaccurate claim about chemotherapy, prognosis, screening, or alternative medicine can influence how patients and families understand their options, whether the error was deliberate or not. That is why responsible cancer reporting depends not only on avoiding deliberate falsehoods, but also on checking sources, verifying medical claims, and clearly separating established evidence from speculation or personal opinion. The royal diagnoses brought cancer into millions of living rooms and conversations. That visibility can be a positive force. It can encourage people to pay attention to their health, to ask questions, and to support research and care. But with that attention comes responsibility. When reporting on cancer, an inaccurate statement about treatment or diagnosis is more than just a factual error. For someone making decisions about their own health, it can shape expectations, influence behavior, and either build or erode trust in medicine. The study’s message is broader than the headlines surrounding King Charles or Princess Catherine. Cancer information matters. The source matters. And when health information reaches millions of people, accuracy matters even more.